{
    "title": "107_hr698",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Prescription Reimportation, \nImprovement, Correction, and Enhancement Act''.\n\nSEC. 2. AMENDMENTS TO PROGRAM FOR IMPORTATION OF CERTAIN PRESCRIPTION \n              DRUGS BY PHARMACISTS AND WHOLESALERS.\n\n    Section 804 of the Federal Food, Drug, and Cosmetic Act (as added \nby section 745(c)(2) of Public Law 106-387) is amended--\n            (1) by striking subsections (e) and (f) and inserting the \n        following subsections:\n    ``(e) Testing; Approved Labeling.--\n            ``(1) Testing.--Regulations under subsection (a)--\n                    ``(A) shall require that testing referred to in \n                paragraphs (6) through (8) of subsection (d) be \n                conducted by the importer of the covered product \n                pursuant to subsection (a), or the manufacturer of the \n                product;\n                    ``(B) shall require that, if such tests are \n                conducted by the importer, information needed to \n                authenticate the product being tested be supplied by \n                the manufacturer of such product to the importer; and\n                    ``(C) shall provide for the protection of any \n                information supplied by the manufacturer under \n                subparagraph (B) that is a trade secret or commercial \n                or financial information that is privileged or \n                confidential.\n            ``(2) Approved labeling.--For purposes of importing a \n        covered product pursuant to subsection (a), the importer \n        involved may use the labeling approved for the product under \n        section 505, notwithstanding any other provision of law.\n    ``(f) Discretion of Secretary Regarding Testing.--The Secretary may \nwaive or modify testing requirements described in subsection (d) if, \nwith respect to specific countries or specific distribution chains, the \nSecretary has entered into agreements or otherwise approved \narrangements that the Secretary determines ensure that the covered \nproducts involved are not adulterated or in violation of section \n505.'';\n            (2) by striking subsections (h) and (i) and inserting the \n        following subsections:\n    ``(h) Prohibited Agreements; Nondiscrimination.--\n            ``(1) Prohibited agreements.--No manufacturer of a covered \n        product may enter into a contract or agreement that includes a \n        provision to prevent the sale or distribution of covered \n        products imported pursuant to subsection (a).\n            ``(2) Nondiscrimination.--No manufacturer of a covered \n        product may take actions that discriminate against, or cause \n        other persons to discriminate against, United States \n        pharmacists, wholesalers, or consumers regarding the sale or \n        distribution of covered products.\n    ``(i) Study and Report.--\n            ``(1) Study.--The Comptroller General of the United States \n        shall conduct a study on the imports permitted under this \n        section, taking into consideration the information received \n        under subsection (a). In conducting such study, the Comptroller \n        General shall--\n                    ``(A) evaluate importers' compliance with \n                regulations, determine the number of shipments, if any, \n                permitted under this section that have been determined \n                to be counterfeit, misbranded, or adulterated; and\n                    ``(B) consult with the United States Trade \n                Representative and United States Patent and Trademark \n                Office to evaluate the effect of importations permitted \n                under this section on trade and patent rights under \n                Federal law.\n            ``(2) Report.--Not later than 5 years after the effective \n        date of final regulations issued pursuant to this section, the \n        Comptroller General of the United States shall prepare and \n        submit to Congress a report containing the study described in \n        paragraph (1).'';\n            (3) in subsection (k)(2)--\n                    (A) by redesignating subparagraphs (A) through (E) \n                as subparagraphs (B) through (F), respectively; and\n                    (B) by inserting before subparagraph (B) (as so \n                redesignated) the following subparagraph:\n                    ``(A) The term `discrimination' includes a contract \n                provision, a limitation on supply, or other measure \n                which has the effect of providing United States \n                pharmacists, wholesalers, or consumers access to \n                covered products on terms or conditions that are less \n                favorable than the terms or conditions provided to any \n                foreign purchaser of such products.'';\n            (4) by striking subsection (m); and\n            (5) by inserting after subsection (l) the following \n        subsection:\n    ``(m) Funding.--For the purpose of carrying out this section, there \nare authorized to be appropriated such sums as may be necessary for \nfiscal year 2002 and each subsequent fiscal year.''."
}